[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SEARCH Research Foundation\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,38,60,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100267466","post-analytic-treatment-interruption-study-100267466",false,"NCT02761200","Post Analytic Treatment Interruption Study","Safety and Virologic Outcomes After HIV Remission Trials in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection","Inclusion Criteria:\n\n* Man or woman aged ≥18 years.\n* Enrolled in RV254 study.\n* Completed clinical research protocol that included ATI within one month of enrollment in this protocol.\n* Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.\n* Able to participate in study visits for up to 144 weeks.\n* Willing to have photo or fingerprint taken for identification purposes.\n* Female-specific criteria: Agrees not to become pregnant while not receiving ART. If a woman is sexually active and has no history of hysterectomy or tubal ligation or menopause, she must agree to engage in abstinence, use a prescription birth control method or use a barrier birth control method while not receiving ART.\n\nExclusion Criteria:\n\n* History of a medical or psychiatric condition that, in the opinion of investigator, would jeopardize the safety or rights of the subject, such as a condition that would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring.",[24],"HIV","RECRUITING","2026-04-22",{"date":28,"type":29},"2026-04-27","ACTUAL",{"date":31,"type":4},"2016-03",{"date":33,"type":20},"2031-03",{"name":35,"class":36},"SEARCH Research Foundation","OTHER",1,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":16,"minAge":17,"maxAge":45,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":37},"100163220","characteristics-of-immunity-in-gut-mucosa-spinal-fluid-lymph-node-and-blood-of-hiv-negative-thais-and-thais-with-hiv-infection-100163220","NCT01397669","Characteristics of Immunity in Gut Mucosa, Spinal Fluid, Lymph Node and Blood of HIV Negative Thais and Thais With HIV Infection","Inclusion Criteria:\n\n1. Age 18 to 50 years old\n2. HIV negative subjects must have negative results by 4th generation EIA and NAT (Aptima)\n3. HIV positive subjects must have a positive 4th generation EIA and a positive less sensitive EIA.\n4. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a study staff and they can give informed consent by using thumb print.\n\nExclusion Criteria:\n\n1. Have gastrointestinal disorders or gastrointestinal symptoms that require endoscopy for diagnostic purposes or have systemic disorders, which include but may not be limited to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus or psoriasis, that in the judgment of investigators could cause colon mucosa to be abnormal on biopsy\n2. Active AIDS-defining opportunistic infection (OI) within 30 days prior to entry for HIV-positive subjects. Subjects must be off all acute treatments for OI for at least 14 days prior to entry. Subjects on maintenance or prophylactic therapy for AIDS-related OIs will be eligible.\n3. Have platelet count \\\u003C 150,000 count\u002Fml or PT, PT\u002FPTT \\> the upper limit of normal (ULN) or INR \\> 1.1\n4. Have self-reported bleeding disorder\n5. Untreated syphilis infection\n6. Abnormal screening neurological examination suggestive of central neurological findings if planning to participate in the lumbar puncture\n7. Positive urine pregnancy test\n8. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.",true,"50 Years",{"count":47,"type":20},232,"INTERVENTIONAL",[50],"NA","To compare the immunophenotyping and immunochemistry in the gut mucosa of HIV negative and non-acute HIV-infected adults\n\n1. To compare the immunophenotyping of the gut mucosa to that of the peripheral blood in HIV negative and in non-acute HIV-infected subjects\n2. To compare the immunophenotyping of the peripheral blood in HIV negative and non-acute HIV-infected adults to the findings from acutely HIV-infected subjects in the WRAIR#1494\u002FRV254\u002F SEARCH 010 study\n3. To compare immunologic markers in the genital compartment compared to the peripheral blood in HIV negative and non-acute HIV-infected adults to the findings from acutely HIV-infected subjects in the WRAIR#1494\u002FRV254\u002F SEARCH 010 study\n4. Archive samples for immunologic and virologic testing",[53],"HIV-infection",{"date":28,"type":29},{"date":56,"type":29},"2011-07",{"date":58,"type":20},"2031-02",{"name":35,"class":36},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":4,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":37},"100117547","establish-and-characterize-an-acute-hiv-infection-cohort-in-a-high-risk-population-100117547","NCT00796146","Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population","Inclusion Criteria:\n\n1. Age \\>18 years old\n2. Have protocol-defined acute HIV-1 infection (Tested 4th generation HIV EIA negative and NAT positive or tested 4th generation HIV EIA positive, negative by less sensitive EIA and NAT positive)\n3. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read to them by a study staff and they can give informed consent by using thumb print.\n4. Availability for follow-up for the planned study duration\n\nExclusion Criteria:\n\n1. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.\n2. Female participants who are pregnant at the time of screening",{"count":67,"type":20},777,"To describe clinical, immunological, and virological characteristics of persons with acute HIV infection\n\n1. To describe demographics and behavioral risk factors for those identified with acute HIV infection\n2. To describe neurocognitive function and neuroimaging findings in acute HIV infection as well as describe immune response, HIV-1 genotypes and sequences in the cerebrospinal fluid.\n3. To describe the number and characteristics of sexual contacts\n4. To describe the willingness of acute HIV-infected subjects to allow the tracking of their sexual contacts for voluntary HIV counseling and testing (VCT)\n5. To describe immune response, HIV-1 genotypes and sequences in the genital compartment\n6. To describe T cell depletion in the gut mucosa in acute HIV infection and describe the changes in gut T cell during follow up\n7. To archive samples for future investigations including determination of viral evolution, and cell-mediated and humoral immune responses in peripheral blood and mucosal compartments",[70],"Acute HIV Infection",{"date":28,"type":29},{"date":73,"type":29},"2009-04",{"date":75,"type":20},"2033-07",{"name":35,"class":36},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":48,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":37},"100117556","phase-3-antiretroviral-therapy-for-acute-and-chronic-hiv-infection-100117556","NCT00796263","Antiretroviral Therapy for Acute and Chronic HIV Infection","AAHIV","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Enrolled in the SEARCH 010 or 013 protocols with documentation of acute or chronic protocol defined HIV-1 infection and chooses to initiate or continue ART\n3. Understand the study and sign informed consent form. Persons who cannot read will have the consent form read and explained to them by a member of the study staff and they can give informed consent by using their thumb print\n4. Availability for follow-up for the planned study duration\n\nExclusion Criteria:\n\n1\\. Persons who have a history of a medical or psychiatric disorder by investigator's interview and physical examination according to standard practices, that in the judgment of the investigator(s), would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.",{"count":85,"type":20},900,[87],"PHASE3","The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an acute HIV infection cohort in a Thai high-risk population') or in a study of chronic HIV infection (SEARCH 013 protocol 'Characteristics of immunity in gut mucosa, spinal fluid, lymph node and blood of HIV negative and HIV positive Thais').",[70,90],"Chronic HIV Infection",[92,93],"Acute HIV infection","Chronic HIV infection","2025-05-28",{"date":96,"type":29},"2025-06-04",{"date":98,"type":29},"2009-05-13",{"date":100,"type":20},"2033-06",{"name":35,"class":36},""]